A Study of the Efficacy and Safety of Highly Purified Menotrophin Versus Recombinant Follitropin Alfa

This study has been completed.
Sponsor:
Information provided by:
Ferring Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00257556
First received: November 22, 2005
Last updated: February 12, 2010
Last verified: February 2010
Results First Received: January 8, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Infertility
Interventions: Drug: Menotrophin
Drug: Follitropin alfa

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Ninety (90) participants were screened and 80 participants randomized.

Reporting Groups
  Description
Menotrophin Highly purified menotrophin sourced from human menopausal gonadotrophin (hMG)
Follitropin Alfa A genetically engineered substitute for follicle stimulating hormone (recombinant FSH (rFSH)).

Participant Flow:   Overall Study
    Menotrophin     Follitropin Alfa  
STARTED     38     42  
All Patients Treated Population     37 [1]   39 [2]
COMPLETED     24     32  
NOT COMPLETED     14     10  
Adverse Event                 1                 4  
Physician Decision                 6                 0  
Did not meet hCG criterion                 3                 0  
other reason                 4                 6  
[1] Also the safety population. One randomized patient did not receive study medication.
[2] Also the safety population. Three randomized patients did not receive study medication.



  Baseline Characteristics


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With an Ongoing Pregnancy   [ Time Frame: Approx week 13; 9 weeks or more after the 1st positive pregnancy test ]

2.  Primary:   Percentage of Participants With an Ongoing Pregnancy   [ Time Frame: Approx week 13; 9 weeks or more after the first positive pregnancy test ]

3.  Secondary:   Participants With Varying Numbers of Follicles That Were Greater Than or Equal to 17 Millimeters   [ Time Frame: Day 7 and, if appropriate, every 2 days thereafter (Days 9/11/13) ]

4.  Secondary:   Participants With Varying Numbers of Oocytes Retrieved   [ Time Frame: Approximately study day 15 ]

5.  Secondary:   Participants With Varying Numbers of Pronuclear Stage Oocytes   [ Time Frame: Approximately study day 15 ]

6.  Secondary:   Participants With Varying Numbers of Embryos Transferred   [ Time Frame: Approximately study day 17 ]

7.  Secondary:   Participants With Varying Numbers of Embryos Frozen   [ Time Frame: Approximately study day 17 ]

8.  Secondary:   Mean Number of Days Stimulated With Gonadotrophins   [ Time Frame: study days 1 - 13 ]

9.  Secondary:   Pregnancy Outcomes   [ Time Frame: Approximately 10 months ]

10.  Secondary:   Mean Endometrial Thickness   [ Time Frame: Day 7 or 9 or 11 or 13 ]

11.  Secondary:   Mean Estradiol Level   [ Time Frame: Day 7 or 9 or 11 or 13 ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Clinical Development Support
Organization: Ferring Pharmaceuticals
e-mail: DK0-Disclosure@ferring.com


No publications provided


Responsible Party: Clinical Development Support, Ferring Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00257556     History of Changes
Other Study ID Numbers: FE999906 CS004 (PROSPECT), 2004-001307-35
Study First Received: November 22, 2005
Results First Received: January 8, 2010
Last Updated: February 12, 2010
Health Authority: United Kingdom: National Health Service
Germany: Ethics Commission